Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DARLO-C: Grazoprevir/elbasvir for HCV in PWID
NCT02940691Phase 4Terminated
- Sponsor
- The Kirby Institute
- Start
- May 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of grazoprevir in hepatitis C (HCV), sponsored by The Kirby Institute. Primary endpoint: Undetectable HCV RNA at 12 Weeks Post End of Treatment. Started May 2017; status: terminated.
02
Drugs
grazoprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02940691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02940691.